{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:05:18Z","timestamp":1789009518751,"version":"build-2803163510"},"reference-count":104,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is a cancer of plasma cells, characterized by abundant synthesis of monoclonal immunoglobulins and\/or free light chains. Although MM remains incurable, median overall survival has considerably improved over the past 2 decades largely due to the introduction of novel agents, including proteasome inhibitors (PIs) and immunomodulatory drugs. Bortezomib, a reversible boronate PI, was the first Food and Drug Administration\u2013approved PI in MM and subsequently mantle cell lymphoma. Carfilzomib and ixazomib, the former an irreversible epoxyketone and the latter an orally bioavailable reversible PI, have been subsequently approved in MM. Altogether, these drugs represent the first effort to disrupt protein homeostasis as a therapeutic strategy in MM. Although effective, de novo resistance is a recognized phenomenon, and acquired resistance to PI is common, prompting the development of biology-based combination therapies. Based on laboratory evidence of increased, constitutive proteotoxic stress, targeting protein catabolism with single or combination therapies is an effective strategy in MM. In this article, we review the scientific rationale and bases for therapeutic application and effectiveness of Food and Drug Administration\u2013approved and investigational drugs targeting protein homeostasis in MM.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000349","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T01:22:29Z","timestamp":1548811349000},"page":"11-18","source":"Crossref","is-referenced-by-count":11,"title":["Contribution of Inhibition of Protein Catabolism in Myeloma"],"prefix":"10.1097","volume":"25","author":[{"given":"Giada","family":"Bianchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ceb.2013.12.006","article-title":"Sorting out the trash: the spatial nature of eukaryotic protein quality control","volume":"26","year":"2014","journal-title":"Curr Opin Cell Biol"},{"key":"bib3-20230924","first-page":"286","article-title":"Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis","volume":"34","year":"2012","journal-title":"Exp Oncol"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2012.06.016","article-title":"Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications","volume":"325","year":"2012","journal-title":"Cancer Lett"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.semcdb.2009.12.007","article-title":"ERAD substrates: which way out?","volume":"21","year":"2010","journal-title":"Semin Cell Dev Biol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.4049\/jimmunol.157.5.1823","article-title":"Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules?","volume":"157","year":"1996","journal-title":"J Immunol"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1242\/jcs.114.5.845","article-title":"At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules","volume":"114","year":"2001","journal-title":"J Cell Sci"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/sj.emboj.7601009","article-title":"Progressively impaired proteasomal capacity during terminal plasma cell differentiation","volume":"25","year":"2006","journal-title":"EMBO J"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","year":"2006","journal-title":"Blood"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","year":"2007","journal-title":"Cancer Res"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"bib13-20230924","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","year":"2001","journal-title":"Cancer Res"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood-2015-03-575365","article-title":"Promising therapies in multiple myeloma","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib15-20230924","first-page":"4","article-title":"Targeting protein synthesis and degradation in multiple myeloma: a look at what's on the horizon","volume":"13","year":"2017","journal-title":"Am J Hematol Oncol"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: from research tools to drug candidates","volume":"8","year":"2001","journal-title":"Chem Biol"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","year":"2004","journal-title":"Cancer Cell"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","year":"2009","journal-title":"Br J Haematol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1126\/science.7725095","article-title":"Functions of the proteasome: the lysis at the end of the tunnel","volume":"268","year":"1995","journal-title":"Science"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1021\/bi802198q","article-title":"Isolation of mammalian 26S proteasomes and p97\/VCP complexes using the ubiquitin-like domain from HHR23B reveals novel proteasome-associated proteins","volume":"48","year":"2009","journal-title":"Biochemistry"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2010.07.036","article-title":"Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress","volume":"142","year":"2010","journal-title":"Cell"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/0008-5472.CAN-05-0506","article-title":"Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells","volume":"65","year":"2005","journal-title":"Cancer Res"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","year":"2009","journal-title":"Blood"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1189\/jlb.1011497","article-title":"Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors","volume":"92","year":"2012","journal-title":"J Leukoc Biol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cub.2014.06.004","article-title":"Proteasome-mediated processing of NRF1 is essential for coordinate induction of all proteasome subunits and p97","volume":"24","year":"2014","journal-title":"Curr Biol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"R834","DOI":"10.1016\/j.cub.2016.08.008","article-title":"NRF1 can be processed and activated in a proteasome-independent manner","volume":"26","year":"2016","journal-title":"Curr Biol"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molcel.2010.02.029","article-title":"Transcription factor NRF1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells","volume":"38","year":"2010","journal-title":"Mol Cell"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"e01856","DOI":"10.7554\/eLife.01856","article-title":"p97-dependent retrotranslocation and proteolytic processing govern formation of active NRF1 upon proteasome inhibition","volume":"3","year":"2014","journal-title":"Elife"},{"key":"bib33-20230924","first-page":"5","article-title":"The aspartyl protease DDI2 activates NRF1 to compensate for proteasome dysfunction","year":"2016","journal-title":"Elife"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1021\/acscentsci.7b00224","article-title":"Inhibition of NGLY1 inactivates the transcription factor NRF1 and potentiates proteasome inhibitor cytotoxicity","volume":"3","year":"2017","journal-title":"ACS Cent Sci"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10428194.2012.706287","article-title":"Molecular mechanisms of effectiveness of novel therapies in multiple myeloma","volume":"54","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","year":"2007","journal-title":"Blood"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","year":"2013","journal-title":"Haematologica"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","year":"2005","journal-title":"Cancer Cell"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.chembiol.2016.12.016","article-title":"Inhibition of the proteasome \u03b22 site sensitizes triple-negative breast cancer cells to \u03b25 inhibitors and suppresses NRF1 activation","volume":"24","year":"2017","journal-title":"Cell Chem Biol"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood-2015-12-686378","article-title":"Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 part 1","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood.V128.22.2110.2110","article-title":"Final results from a multicenter, open-label, dose-escalation phase 1B\/2 study of single-agent oprozomib in patients with hematologic malignancies","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/blood.V124.21.3453.3453","article-title":"Oprozomib and dexamethasone in patients with relapsed and\/or refractory multiple myeloma: initial results from the dose escalation portion of a phase 1B\/2, multicenter, open-label study","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","year":"2013","journal-title":"Lancet Oncol"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","article-title":"Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells","volume":"108","year":"2006","journal-title":"Blood"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","year":"2003","journal-title":"Cell"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","year":"2012","journal-title":"Blood"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1B trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","article-title":"Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrm2731","article-title":"Breaking the chains: structure and function of the deubiquitinases","volume":"10","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/nm.2536","article-title":"Inhibition of proteasome deubiquitinating activity as a new cancer therapy","volume":"17","year":"2011","journal-title":"Nat Med"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2016.97","article-title":"Targeting proteasome ubiquitin receptor RPN13 in multiple myeloma","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","article-title":"A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"26979","DOI":"10.1038\/srep26979","article-title":"The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells","volume":"6","year":"2016","journal-title":"Sci Rep"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","year":"2012","journal-title":"Cancer Cell"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/embj.201386906","article-title":"Autoubiquitination of the 26S proteasome on RPN13 regulates breakdown of ubiquitin conjugates","volume":"33","year":"2014","journal-title":"EMBO J"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the pathogenesis of disease","volume":"132","year":"2008","journal-title":"Cell"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1158\/1535-7163.MCT-08-1177","article-title":"Effect of autophagy on multiple myeloma cell viability","volume":"8","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"bib64-20230924","first-page":"643","article-title":"Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress","volume":"38","year":"2011","journal-title":"Int J Oncol"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neulet.2009.03.085","article-title":"Inhibition of lysosomal functions reduces proteasomal activity","volume":"456","year":"2009","journal-title":"Neurosci Lett"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"e25820","DOI":"10.1371\/journal.pone.0025820","article-title":"Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells","volume":"6","year":"2011","journal-title":"PloS one"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/15548627.2015.1052928","article-title":"A plastic SQSTM1\/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells","volume":"11","year":"2015","journal-title":"Autophagy"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1083\/jcb.201708168","article-title":"Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation","volume":"217","year":"2018","journal-title":"J Cell Biol"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2016.08.019","article-title":"Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo","volume":"382","year":"2016","journal-title":"Cancer Lett"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.4161\/auto.29264","article-title":"Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma","volume":"10","year":"2014","journal-title":"Autophagy"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)","volume":"12","year":"2016","journal-title":"Autophagy"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: from stress pathway to homeostatic regulation","volume":"334","year":"2011","journal-title":"Science (New York, NY)"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/nrd2755","article-title":"Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities","volume":"7","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/ncb1996","article-title":"Adaptive suppression of the ATF4-CHOP branch of the unfolded protein response by Toll-like receptor signalling","volume":"11","year":"2009","journal-title":"Nat Cell Biol"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0092-8674(01)00611-0","article-title":"XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor","volume":"107","year":"2001","journal-title":"Cell"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1128\/MCB.23.21.7448-7459.2003","article-title":"XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response","volume":"23","year":"2003","journal-title":"Mol Cell Biol"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"XBP1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","year":"2013","journal-title":"Cancer Cell"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/blood-2010-08-303099","article-title":"Identification of an IRE1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma","volume":"117","year":"2011","journal-title":"Blood"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/emboj.2011.18","article-title":"Structure of the IRE1 autophosphorylation complex and implications for the unfolded protein response","volume":"30","year":"2011","journal-title":"EMBO J"},{"key":"bib80-20230924","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1038\/bcj.2013.2","article-title":"Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance","volume":"3","year":"2013","journal-title":"Blood Cancer J"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood-2018-05-851170","article-title":"Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib82-20230924","doi-asserted-by":"crossref","first-page":"e74415","DOI":"10.1371\/journal.pone.0074415","article-title":"Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells","volume":"8","year":"2013","journal-title":"PloS One"},{"key":"bib83-20230924","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1158\/1535-7163.MCT-17-0233","article-title":"The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of multiple myeloma","volume":"16","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"bib84-20230924","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jcb.240240104","article-title":"The ubiquitin-mediated proteolytic pathway and mechanisms of energy-dependent intracellular protein degradation","volume":"24","year":"1984","journal-title":"J Cell Biochem"},{"key":"bib85-20230924","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrm.2016.91","article-title":"Structural insights into the catalysis and regulation of E3 ubiquitin ligases","volume":"17","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"bib86-20230924","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrm3919","article-title":"Protein neddylation: beyond Cullin-RING ligases","volume":"16","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"bib87-20230924","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00280-018-3541-8","article-title":"Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases","volume":"81","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib88-20230924","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1535-7163.MCT-11-0563","article-title":"Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma","volume":"11","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"bib89-20230924","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","article-title":"Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma","volume":"22","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.1073\/pnas.0510496103","article-title":"Hsp70 chaperones accelerate protein translocation and the unfolding of stable protein aggregates by entropic pulling","volume":"103","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib91-20230924","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nature04600","article-title":"CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70","volume":"440","year":"2006","journal-title":"Nature"},{"key":"bib92-20230924","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/j.biocel.2004.02.013","article-title":"Mechanisms of chaperone-mediated autophagy","volume":"36","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1146\/annurev.ge.22.120188.003215","article-title":"The heat-shock proteins","volume":"22","year":"1988","journal-title":"Annu Rev Genet"},{"key":"bib94-20230924","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1158\/1078-0432.CCR-17-1594","article-title":"HSF1 is essential for myeloma cell survival and a promising therapeutic target","volume":"24","year":"2018","journal-title":"Clin Cancer Res"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S1470-2045(13)70169-4","article-title":"Inhibition of HSP90 molecular chaperones: moving into the clinic","volume":"14","year":"2013","journal-title":"Lancet Oncol"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.2010.08264.x","article-title":"Tanespimycin with bortezomib: activity in relapsed\/refractory patients with multiple myeloma","volume":"150","year":"2010","journal-title":"Br J Haematol"},{"key":"bib97-20230924","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/cncr.29339","article-title":"Phase 1\/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma","volume":"121","year":"2015","journal-title":"Cancer"},{"key":"bib98-20230924","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.18632\/oncotarget.1584","article-title":"Heat shock proteins in multiple myeloma","volume":"5","year":"2014","journal-title":"Oncotarget"},{"key":"bib99-20230924","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"bib100-20230924","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","year":"2010","journal-title":"Science"},{"key":"bib101-20230924","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","year":"2014","journal-title":"Science"},{"key":"bib102-20230924","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","year":"2014","journal-title":"Science"},{"key":"bib103-20230924","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","year":"2015","journal-title":"Science"},{"key":"bib104-20230924","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","article-title":"The dTAG system for immediate and target-specific protein degradation","volume":"14","year":"2018","journal-title":"Nat Chem Biol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201901000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T11:59:20Z","timestamp":1720958360000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201901000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000349","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}